Vitamin D Deficiency: Consequence or Cause of Obesity? by Vranić, Luka et al.
medicina
Review
Vitamin D Deficiency: Consequence or Cause
of Obesity?
Luka Vranic´, Ivana Mikolaševic´ and Sandra Milic´ *
Department of Gastroenterology and Hepatology, University Hospital Centre Rijeka, School of Medicine,
University of Rijeka, 51000 Rijeka, Croatia
* Correspondence: smilic05@gmail.com
Received: 30 June 2019; Accepted: 22 August 2019; Published: 28 August 2019


Abstract: Obesity is defined as an excess amount of body fat and represents a significant health problem
worldwide. High prevalence of vitamin D (VD) deficiency in obese subjects is a well-documented
finding, most probably due to volumetric dilution into the greater volumes of fat, serum, liver, and
muscle, even though other mechanisms could not completely be excluded, as they may contribute
concurrently. Low VD could not yet be excluded as a cause of obesity, due to its still incompletely
explored effects through VD receptors found in adipose tissue (AT). VD deficiency in obese people
does not seem to have consequences for bone tissue, but may affect other organs, even though studies
have shown inconsistent results and VD supplementation has not yet been clearly shown to benefit
the dysmetabolic state. Hence, more studies are needed to determine the actual role of VD deficiency
in development of those disorders. Thus, targeting lifestyle through healthy diet and exercise should
be the first treatment option that will affect both obesity-related dysmetabolic state and vitamin D
deficiency, killing two birds with one stone. However, VD supplementation remains a treatment
option in individuals with residual VD deficiency after weight loss.
Keywords: vitamin D; obesity; deficiency
1. Introduction
Vitamin D (VD) is essential for the maintenance of bone tissue, as well as for homeostasis of
the minerals calcium and phosphorus. Its receptors have been found all over the human body
indicating multiple functions. Since body VD is mainly result of endogenous synthesis it is nowadays
often considered as a hormone more than vitamin in the narrow sense. The active form of VD,
1,25-dihydroxyvitamin D (1,25(OH)2D), not only stimulates calcium absorption, osteoclastic bone
resorption, and osteoblast function and decreases PTH (parathyroid hormone) secretion but also has
extraskeletal functions such as decreasing collagen type 1 production, enhancing muscular function,
and stimulating cell differentiation, insulin secretion, and the immune system [1]. A severe lack of VD
causes osteomalacia in adults and rickets in children, while a less severe deficiency leads to increased
bone turnover and consequently a greater risk of bone fractures. Lately, VD deficiency, defined as a
serum concentration of 25-hydroxyvitamin D (25(OH)D) below 50 nmol−1 or 20 ng mL−1 [2,3], has
been associated with numerous disorders, such as cardiovascular diseases, arterial hypertension,
dyslipidemia, type 2 diabetes, cancer, multiple sclerosis, depression, dementia, psychiatric diseases,
and others [4]. Hence, today, VD and its unclear role in the pathogenesis and progression of those
disorders represent a trend in scientific research.
Obesity is defined as an excess amount of body fat and represents a significant health problem
world-wide. The association between VD deficiency and obesity as well as with obesity-related diseases
has been confirmed by numerous studies, but the presence of a causal relationship is still unclear.
There are many possible explanations regarding the inverse relationship between increased adiposity,
Medicina 2019, 55, 541; doi:10.3390/medicina55090541 www.mdpi.com/journal/medicina
Medicina 2019, 55, 541 2 of 10
particularly abdominal obesity, and low plasma VD concentrations, as discussed below, but so far
none of these hypotheses can completely elucidate this relation. Therefore, it is possible that several
mechanisms have an impact on the interaction between VD, obesity, and related diseases. Hence, more
studies are needed to investigate each one, not only to investigate the causal relationship, but also to
identify and establish VD supplementation treatment that could possibly positively affect adiposity
and related disorders. However, so far, studies have shown inconsistent results regarding the clinical
implication of VD supplementation, which raises the following main question. Is VD deficiency only a
coincidental finding in obese subjects or could it actually have an important role in the development
and progression of obesity and chronic illnesses?
2. Clinical Consequences of Lower 25(OH)D
A low plasma level of VD usually leads to impaired calcium absorption in the bowel and a lower
plasma calcium level, which consequently leads to enhanced bone turnover and impaired bone mineral
density (BMD). However, obese subjects have a greater BMD then lean people, as well as greater cortical
thickness and cortical tissue mineral density. Hence, obesity has a positive impact on peak bone mass
acquisition [5]. The lack of VD deficiency consequences on bones may indicate that, in fact, although
the plasma 25OHD level is usually lower, obese people are actually not VD insufficient. The greater VD
reservoir in obese people can possibly act as a permanent supply that consequently maintains bone
turnover. On the other hand, greater skeletal loading and actions of hormones such as estrogen, leptin,
and adiponectin could compensate for an eventual VD deficiency, leading to a greater BMD [6].
Low VD is also associated with poor health behaviors. Recently, its deficiency has been associated
with a large number of disorders such as metabolic syndrome, cancers, and autoimmune, psychiatric,
and neurodegenerative diseases, but the causative role of VD deficiency in many of these conditions
remains unclear [7]. Since VD deficiency is related to visceral adiposity; it could be used as a
biomarker of a visceral adiposity-related dysmetabolic state (cardiovascular diseases, type 2 diabetes,
dyslipidemia, arterial hypertension) (Figure 1). Nevertheless, its independent role in the development
and progression of these diseases cannot yet be excluded, due to changes in the expression of genes
regulated with VD receptors. Moreover, as stated below, in VD deficient subjects, the lack of possible
anti-inflammatory effects on chronic low-grade inflammation could lead to an enhanced risk of
obesity-related metabolic disorders.
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3. Causes of Low 25-Hydroxyvitamin D in Obese Patients
Nowadays, volumetric dilution of VD is the most probable mechanism of the inverse relationship
between vitamin D serum levels and BMI. Even though obese and lean subjects have similar amounts of
VD, in overweight people, VD is distributed into a larger volume, making serum concentrations lower.
Namely, 25(OH)D is distributed dominantly into the serum, muscle, fat, and liver—compartments that
are increased in obesity [6]. The explanation for this could be found in the fact that seasonal variation
has a large impact on the difference in serum 25(OH)D concentration between normal weight and
obese groups. According to Bolland et al. [8], the difference is greater in summer, because the increase
in 25(OH)D serum levels due to sunlight exposure is less in obese people in comparison to normal
weight groups because of distribution to compartments other than serum. Moreover, another study
reported a smaller 25(OH)D rise in serum in obese than in normal weight people in response to VD
supplementation [9]. Accordingly, Drincic et al. [10] suggest that VD supplementation needs to be
adjusted for body size in order to erase the serum rise difference between obese and lean subjects. In
addition, in their study, the 25(OH)D response after VD supplementation was approximately 30%
lower in the obese group. Carelli et al. [11] measured the concentration of VD in the plasma and
omental and subcutaneous tissue in both obese individuals and a control group, and they found that
the relationship between plasma VD and the VD concentrations in the subcutaneous and omental fat
compartments was similar between both groups and that the pattern of distribution of VD between
those two fat tissues was also similar, indicating that adipose tissue (AT) does act as a reservoir for
VD. However, if volumetric dilution is the main cause of low 25(OH)D in obese people, this suggests
that weight loss would, consequently, increase VD serum levels. Nevertheless, weight loss studies
show inconsistent results. Some report increased 25OHD serum levels [12,13]; while, on the other
hand, others show insignificant increases in serum levels. Mason et al. [14] conducted a weight loss
study on a large number of obese postmenopausal participants (N = 398) who underwent a 12 month
long weight loss plan involving calorie restriction and exercise and showed that weight loss increased
25(OH)D serum levels insignificantly. However, in the group of women who lost more than 15% of
their body weight, 25(OH)D significantly increased (7.7 ng/mL), which suggests that there may be a
threshold of weight loss that can positively alter the VD serum concentration.
On the other hand, VD sequestration in adipose tissue (AT) hypothesis was introduced by
Wortsman et al. [15] who demonstrated that even though dermal synthesis of VD does not differ
between two groups, obese subjects have lower increments in plasma levels of 25(OH)D after sunlight
exposure and oral supplementation of VD compared to normal weight subjects. They suggested that
VD, as a fat-soluble vitamin, is accumulated and retained in AT, which leads to lower plasma levels of
VD in people with a large amount of AT. This sequestration hypothesis was the basis for the volumetric
dilution hypothesis that is discussed previously. However, in comparison to volumetric dilution,
sequestration of the prohormones ergocalciferol (VD2) and cholecalciferol (VD3) refers not only to
their hydrophobic nature and tendency to dissolve in AT but also refers to their inability to regress into
the circulation as a substrate for liver 25-hydroxylase, which converts these prohormones to 25(OH)D
once they are stored [16].
Another possible mechanism for lower 25(OH)D is impaired hepatic 25-hydroxylation. Targher
et al. [17] reported that 25-hydroxylation is impaired in patients with non-alcoholic fatty liver disease
(NAFLD), a condition that is very common in obesity. In addition, they found that decreased
25(OH)D serum concentrations are closely related to the severity of histologically proven liver steatosis,
inflammation, and necrosis. However, recently NAFLD has become the most common form of chronic
liver disease and, consequently, the leading cause of liver cirrhosis. Since it is strongly associated with
obesity and metabolic syndrome, large randomized, placebo-controlled trials are needed to confirm
the relation between this condition and low 25OHD and to evaluate the possible positive effect of VD
supplementation [4,18].
Furthermore, one study was performed in order to elucidate whether low serum levels of VD in
obese people could be due altered VD metabolism in AT. They showed that there is a difference in gene
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expression in VD metabolizing enzymes between normal weight and obese people, which suggests
that AT could be involved in the metabolism of VD and does not only passively store fat-soluble
nutrients. In fact, they found a 71% (p < 0.0001) decrease in the expression of the cytochrome P450 2J2
gene, which codes for the enzyme 25-hydroxylase, and a 49% (p < 0.05) decrease in the expression of
cytochrome P450 27B1, which codes for the enzyme 1a-hydroxylase in the subcutaneous AT of the
obese group compared to lean subjects [12,16]. Since these enzymes play roles in particular steps of
hydroxylation or in the conversion of prohormones into bioactive form, the observation of a decrease
in gene coding for them would implicate a deficit of the VD bioactive form and a reduced effect in
the body. Moreover, the difference in the expression of cytochrome P450 24A1, which codes for the
enzyme responsible for inactivation of 1,25(OH)2D (a bioactive form), was not observed between
obese and normal weight groups. Nevertheless, after weight loss the expression of this gene was
increased by 79%. This upregulation of VD inactivating genes after weight loss and downregulation
of bioactivating genes in obesity may suggest involvement of AT in VD metabolism. In addition,
these contrary findings represent a puzzling phenomenon and require further research as to whether
gene expression differences lead to altered VD metabolism, and if that proves true, whether the local
AT metabolism of VD could actually impact the circulating levels of 25(OH)D. Moreover, the lack of
bioactivating enzymes in AT indicates that volumetric dilution is not the only reason why obese people
need higher doses of VD in order to achieve target concentrations [16].
Considering that skin synthesis of cholecalciferol through ultraviolet B (UVB) radiation from sun
exposure is the main source of VD (80–90%) [3], the low concentration of 25(OH)D, the circulating
form of VD that is usually measured in trials due to its relatively long half-life, observed in obese
individuals could be explained by less sunlight exposure due to their lower mobility and participation
in outdoor activities and different clothing habits than normal weight people [6,16]. Two UK studies,
on the other hand, affirmed that sunlight exposure between normal weight people and obese people
does not vary [19,20]. Another study reported that, when exposed to UVB, cutaneous synthesis of VD
is similar among people with different body mass index (BMI) values [15] (Figure 2). Nevertheless,
due to geographic and cultural differences sun exposure could have impact on VD synthesis and
consequently serum levels in some groups.
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Adverse dietary habits are common in obesity, which could lead to a lower intake of VD. Since
dietary sources are minor contributor to total VD intake in humans, this explanation is less probable [21].
Moreover, Walsh et al. [6,19] reported that the dietary intake of VD in the UK population does not
differ between obese and normal weight people. Thus, diet is most probably irrelevant factor even
though its minor contribution to low VD levels could not be completely excluded.
Lately, there have been some studies and experimental data that support the hypothesis that
VD could be involved in the pathogenesis of obesity, rather than just being a consequence. Some
experimental data suggest that an increased level of parathyroid hormone, due to VD deficiency,
promotes lipogenesis by greater calcium inflow in adipocytes [3,22]. Another, more probable, hypothesis
is that the active form of VD, 1,25(OH)D, inhibits adipogenesis through actions modulated by VD
receptors [3,23]. Blumberg et al. [24] demonstrated that in 3T3-L1 preadipocytes, in the presence
of 1,25(OH)D, VD receptors inhibited differentiation by downregulating the adipocyte promoting
transcription factor C/EBPβ. Furthermore, 1,25(OH)D is able to maintain the WNT/β-catenin pathway,
which is downregulated during adipogenesis, and thus can inhibit adipogenesis [25]. Therefore, lower
VD levels could lead to enhanced differentiation of pre-adipocytes to adipocytes. Moreover, two
independent longitudinal studies showed that a lower VD concentration predisposes an individual to
obesity and is associated with greater weight gain compared to subjects with weight gain but a higher
baseline VD [26,27]. Due to lack of clinical studies, the exact role of VD deficiency in development and
predisposition to obesity still remains questionable. It is definitely more probable that VD deficiency is
just a consequence due to volumetric dilution and other causes but, since experimental data showed
promising results, involvement in pathogenesis could not be excluded. Therefore, more prospective
randomized controlled trials are needed, because if involvement is proven, that could possibly establish
VD supplementation as a treatment option in preventing obesity, even though VD supplementation
trials show inconsistent results, as discussed below.
4. Effects of Vitamin D Supplementation
Since a low VD could contribute, or at least is related to dysmetabolic condition and related
diseases, as discussed previously, the main question remains: Could VD supplementation therapy
have long-term health benefits for visceral adiposity-related disease patients?
Numerous studies have demonstrated conflicting results regarding the management of
adiposity-related diseases with VD supplementation. Zittermann et al. [28] demonstrated that
VD supplementation does not adversely affect bodyweight, but it could significantly improve several
cardiovascular risk markers. Other studies also showed no effect of VD treatment on bodyweight
reduction and body composition [29–31]. These findings indicate that, even though a low VD
concentration is associated with obesity, the association is not bidirectional.
Studies suggest that an increase in plasma VD is not associated with a significant increase in blood
pressure [29,32,33]. VD therapy has shown inconsistent findings in managing adverse lipid profile,
namely, higher triglycerides, total, and LDL cholesterol concentrations and a lower HDL concentration.
One double blind, placebo controlled randomized clinical trial demonstrated no effect of increased
25(OH)D on the lipid profile in obese patients [29], while another study noted an enhanced impact of VD
supplementation on the decrease of serum triglycerides in healthy obese patients during weight loss [28].
Epidemiological, experimental, and clinical studies also suggest a possible key role of chronic
low-grade inflammation in the development of metabolic syndrome features, such as type 2
diabetes [34] and cardiovascular diseases [35]. Two studies on adipose tissue cultures demonstrated
anti-inflammatory effects of 1,25(OH)2D under experimental conditions [36,37]. If anti-inflammatory
effects could be proven in vivo, this would suggest that either low VD is a cause and/or that increasing
the plasma VD concentration could reduce low-grade inflammation, as seen as a decrease in circulatory
inflammatory markers. In obese subjects, during a weight loss trial, year-long daily supplementation
of 3332 IU VD augmented the decrease in TNFα, but decreases in CRP and IL-6 were not observed
compared to a placebo [28], and in patients with congestive heart failure, ingestion of 2000 UI of VD
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daily for 9 months decreased plasma TNFα, increased IL-10, and did not affect CRP [38]. Conversely,
Pittas et al. [39] demonstrated that daily treatment of 700 IU VD and 500 mg calcium for 3 years did not
affect circulating levels of cytokines. Moreover, Wamberg et al. [36] reported that a daily VD dose of
7000UI for 26 weeks affected neither the expression of inflammatory markers in AT, nor concentrations
of circulating cytokines. Since clinical studies, in opposite to experimental studies, did not show
decreases in inflammatory markers levels, or at least results were inconsistent, VD supplementation is
not recommended for that matter, even though more studies are needed.
Insulin resistance is a commonly seen condition in obese people and predisposes individuals to
the development of type 2 diabetes. Inconsistent findings have been reported regarding the effect
of VD supplementation on insulin resistance. Several cross-sectional studies have shown that VD
deficiency is associated with hyperglycemia [40,41], hyperinsulinemia [42], impaired β-cell function,
and insulin resistance [43]. Von Hurst et al. [44] found decreased HOMA-IR after VD treatment in
overweight and insulin resistant women, but also found no effect on the fasting glucose level, lipid
profile, and inflammatory markers. However, other trials have demonstrated a lack of effect of VD
treatment on insulin resistance. Wamberg et al. [29] found no effect on insulin resistance after 26 weeks
of treatment with 7000 UI of cholecalciferol, while another prospective observational study actually
reported an association between low VD and the development of type 2 diabetes, which became
insignificant after adjustment for BMI [45]. In VD deficient men, short term treatment with high doses
of cholecalciferol did not improve insulin resistance measured with HOMA-IR [46]. These contrasting
findings suggest that further studies are required in order to establish whether VD supplementation is
a possible treatment for people who are predisposed to type 2 diabetes.
Wamberg et al. [29] also explored the effects of VD supplementation on ectopic fat accumulation
by measuring the hepatic lipid content with MR spectroscopy and reported that the concentration of
intrahepatic lipids strongly correlates with insulin resistance and consequently with the development
of type 2 diabetes and cardiovascular incidents. These findings are consistent with another study that
found a correlation between the severity of NAFLD based on histopathological analysis and a low
plasma VD concentration [17]. Nevertheless, in their study, Wamberg et al. did not find a decrease in
intrahepatic fat accumulation after VD treatment. Based on their findings they suggest that steatotic
liver, a common feature in obesity, is associated with a decreased capacity for the hydroxylation of
prohormones into 25(OH)D.
In Table 1 are studies that investigated the association between obesity and VD.
Table 1. Studies that investigated the connection between obesity and vitamin D.
Ref Study Design Study Size Major Findings
Evans et al. [5] Cross-sectionalcase-control study 200
Obesity has a positive impact on peak bone
mass acquisition and also obese subjects have
greater cortical thickness and cortical tissue
mineral density.
Bolland et al. [8] Cross-sectional study 1984 Vitamin D serum levels showseasonal variations.
Gallagher et al. [9]
Randomized,
double-blind placebo
controlled study
163
Obese subjects respond with smaller
25(OH)D rise in serum after VD
supplementation in comparison to normal
weight group.
Drincic et al. [10] Randomized,single-blind study 67
25(OH)D response after VD supplementation
is 30% lower in the obese group. VD
supplementation should be adjusted
according for body size.
Wamberg et al. [12] Cross-sectional study 40
Due to different expression of liver enzymes
between obese and normal weight groups,
adipose tissue can metabolize VD locally
which can be altered after weight loss.
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Table 1. Cont.
Ref Study Design Study Size Major Findings
Rock et al. [13] Prospective randomizedclinical trial 383
Weight loss increases 25(OH)D serum
concentration
Mason et al. [14] Prospective randomizedcontrolled trial 439
Weight loss of 15% of body weight and above
increases 25(OH)D significantly, otherwise
weight loss does not impact on serum
25(OH)D
Walsh et al. [19] Cross-sectionalobservational study 223
Total and free 25(OH)D and 1,25(OH)2D are
lower at higher BMI does not impact bone
structure and health.
Macdonald et al. [20]
Prospective
observational cohort
study
314
Vitamin D deficiency is not related to reduced
sun exposure in obese woman. Vitamin D
serum concentrations seasonally changes.
LeBlanc et al. [26] Prospective longitudinalstudy 9704
Vitamin D deficiency predisposes for obesity,
higher doses of VD are related to lower
weight gain
Mai et al. [27] Cross-sectional andprospective cohort study 25,616
Low plasma 25(OH)D level (less than 50
nmol/L) was related to higher BMI and waist
circumference.
Zittermann et al. [28]
Randomized,
double-blind placebo-
controlled study
200
VD supplementation has positive impact on
several cardiovascular disease risk markers in
obese, but does not adversely affect
weight loss
Wamberg et al. [29]
Randomized,
double-blind placebo-
controlled study
52
VD supplementation has no effect on
obesity-related complication nor on body
weight reduction.
Kampmann et al. [30]
Randomized,
double-blind placebo-
controlled study
16
VD supplementation does not improve
insulin resistance, blood pressure,
inflammation or HbA1c, but might increase
insulin secretion.
Mason et al. [31]
Randomized,
double-blind placebo-
controlled study
218 VD supplementation does not reducebody weight.
Wamberg et al. [36]
Randomized,
double-blind placebo-
controlled study
40
Inflammatory cytokines and inflammatory
markers expression in adipose tissue were
not reduced after VD supplementation,
nevertheless it had significant inflammatory
effects in AT in vitro.
Schleithoff et al. [38]
Randomized,
double-blind placebo-
controlled study
123
Improvement of VD status decreased plasma
proinflammatory cytokines in patients with
congestive heart failure.
Pittas et al. [39]
Randomized,
double-blind placebo-
controlled study
314
VD and calcium supplementation did not
affect circulating levels of cytokines but
attenuate increases in glycemia and insulin
resistance in nondiabetic subjects.
Baynes et al. [42]
Prospective
population-based
cross-sectional study
142 VD hypovitaminosis is associated tohyperglycemia.
van Hurst et al. [44]
Randomized,
double-blind placebo-
controlled study
81
VD supplementation improves insulin
sensitivity, but has no effect on insulin
secretion.
Drincic et al. [47] Cross-sectional study 686
Body weight and VD plasma levels are
conversely associated due to
volumetric dilution.
Vitamin D (VD).
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5. Conclusions
The high prevalence of VD deficiency in obese subjects is a well-documented finding that is
most probably due to volumetric dilution into the greater volumes of fat, serum, liver, and muscle
present in obese people. However, other mechanisms cannot completely be excluded, as they may
contribute concurrently. A low VD concentration cannot yet be excluded as a cause of obesity due to
the incompletely explored effects of VD receptors found in AT. VD deficiency in obese people does not
seem to have consequences for bone tissue, but may affect other organs, even though studies have
shown inconsistent results and VD supplementation has not yet been clearly shown to benefit the
dysmetabolic state. Hence, more studies are needed to determine the actual role of VD deficiency
in the development of these disorders and the effect of VD supplementation. Thus, treatment with
VD still remains controversial. Nevertheless, when it is required, due to volumetric dilution in obese
patients, higher doses of vitamin D are needed to achieve the same serum concentration compared
to lean subjects [47]. Once achieved, the maintenance dose should not differ between the normal
weight and obese groups. However, weight loss is currently the only actually proven treatment that
leads to improvement in a number of disorders, including VD deficiency. Adiposity loss, especially
the loss of visceral fat tissue, has been strongly associated with better health outcomes contributing
to the normalization of insulin resistance, adverse lipid profiles, and arterial hypertension, which
are all features of metabolic syndrome [16]. Thus, targeting lifestyle improvements through the
promotion of a healthy diet and exercise should be the first treatment option, as it will affect both the
obesity-related dysmetabolic state and vitamin D deficiency, killing two birds with one stone. However,
VD supplementation remains a treatment option for individuals with residual VD deficiency after
weight loss.
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